2. Autophagy
  3. Autophagy
  4. 3PO

3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC50s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+ and NADH. 3PO can be used for the research of cancer.

For research use only. We do not sell to patients.

3PO Chemical Structure

3PO Chemical Structure

CAS No. : 18550-98-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 73 In-stock
Solution
10 mM * 1 mL in DMSO USD 73 In-stock
Solid
5 mg USD 66 In-stock
10 mg USD 92 In-stock
25 mg USD 167 In-stock
50 mg USD 251 In-stock
100 mg USD 436 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 21 publication(s) in Google Scholar

3PO Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC50s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+ and NADH. 3PO can be used for the research of cancer[1].

In Vitro

3PO (0-33 μM; 0-36 h) inhibits Jurkat cells proliferation by influence cell cycle[1].
3PO (10 μM/L; 0-36 h) suppresses glycolytic flux to lactate in Jurkat cells[1].
3PO (10 μM/L; 0-36 h) inhibits cellular proliferation of transformed tumor cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3PO Related Antibodies

Cell Proliferation Assay[1]

Cell Line: Jurkat cells
Concentration: 0.3, 1, 3, 10 and 33 μM
Incubation Time: 0, 4, 8, 16, 24 and 36 hours
Result: Inhibited Jurkat T cells proliferation by G2-M phase cell cycle arrest.

Cell Viability Assay[1]

Cell Line: Jurkat cells
Concentration: 0.3, 1, 3, 10 and 33 μM
Incubation Time: 0, 4, 8, 16, 24 and 36 hours
Result: Decreased lactate secretion, NADH, NAD+ and ATP in Jurkat cells.

Cell Proliferation Assay[1]

Cell Line: Jurkat, K562, HL-60, MDA-MB231, HL-60, HeLa, Melanoma and Lewis Lung
Concentration: 0-20 μM
Incubation Time: 0, 4, 8, 16, 24 and 36 hours
Result: Inhibited solid tumor and hematologic cell lines with IC50s of 1.4-24 μM/L.
In Vivo

3PO (0.07 mg/g; i.p. once per day for 14 days) inhibits the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice[1].
3PO (0.07 mg/g; i.p. three sequential daily injections followed by 3 off days for 14 days) inhibits the tumor growth in BALB/c athymic mice[1].
3PO (0.07 mg/g; i.p. two daily injections followed a 7-day rest for 14 days) inhibits the tumor growth in BALB/c athymic mice[1].
3PO (0.07 mg/g; i.p. once) inhibits Fru-2,6-BP and glucose uptake in C57Bl/6 mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C57Bl/6 mice with Lewis lung carcinoma xenografts[1]
Dosage: 0.07 mg/g
Administration: Intraperitoneal injection; 0.07 mg/g once a day; for 14 days
Result: Suppressed the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice compared to the control group.
Animal Model: Female BALB/c athymic mice with MDA-MB231 human breast adenocarcinoma xenografts[1]
Dosage: 0.07 mg/g
Administration: Intraperitoneal injection; 0.07 mg/g three sequential daily injections of either DMSO or 3PO followed by 3 off days; for 14 days
Result: Suppressed xenograft tumorigenic growth of MDA-MB231 cells compared with the controls.
Animal Model: Female BALB/c athymic mice with HL-60 leukemia xenografts[1]
Dosage: 0.07 mg/g
Administration: Intraperitoneal injection; 0.07 mg/g two daily injections followed a 7-day rest; for 14 days
Result: Suppressed xenograft tumorigenic growth of HL-60 leukemia compared with the controls, especially from the second administration cycle.
Animal Model: Female C57Bl/6 mice with Lewis lung carcinoma xenografts[1]
Dosage: 0.07 mg/g
Administration: Intraperitoneal injection; once
Result: Decreased Fru-2,6-BP and glucose uptake in C57Bl/6 mice compared to control group.
Molecular Weight

210.23

Formula

C13H10N2O
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1=CC=NC=C1)/C=C/C2=CC=CN=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 60 mg/mL (285.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.7567 mL 23.7835 mL 47.5670 mL
5 mM 0.9513 mL 4.7567 mL 9.5134 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 3 mg/mL (14.27 mM); Clear solution

    This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 3 mg/mL (14.27 mM); Clear solution

    This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.7567 mL 23.7835 mL 47.5670 mL 118.9174 mL
5 mM 0.9513 mL 4.7567 mL 9.5134 mL 23.7835 mL
10 mM 0.4757 mL 2.3783 mL 4.7567 mL 11.8917 mL
15 mM 0.3171 mL 1.5856 mL 3.1711 mL 7.9278 mL
20 mM 0.2378 mL 1.1892 mL 2.3783 mL 5.9459 mL
25 mM 0.1903 mL 0.9513 mL 1.9027 mL 4.7567 mL
30 mM 0.1586 mL 0.7928 mL 1.5856 mL 3.9639 mL
40 mM 0.1189 mL 0.5946 mL 1.1892 mL 2.9729 mL
50 mM 0.0951 mL 0.4757 mL 0.9513 mL 2.3783 mL
60 mM 0.0793 mL 0.3964 mL 0.7928 mL 1.9820 mL
80 mM 0.0595 mL 0.2973 mL 0.5946 mL 1.4865 mL
100 mM 0.0476 mL 0.2378 mL 0.4757 mL 1.1892 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

3PO Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

3PO18550-98-6Autophagysmall-moleculehuman malignant hematopoieticadenocarcinoma cellchemotherapeutic agentsisozymeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
3PO
Cat. No.:
HY-19824
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.